



Promitheas

Overview of Projects and Activities

January – December 2024


CONTENTS

p. 01_	Who we are
02_	Our mission
03_	Our facilities
04_	People reached through our activities
05_	Projects
06_	- I Deserve to Know
09_	- I Deserve to Know-Plus II
11_	- Viral Hepatitis Multi-Country Community Screening, Vaccination and Care (VH-COMSAVAC)
13_	- Delta Care Project
16_	- It Works for You!
17_	- I Deserve to Know – Prevention – Early diagnosis
19_	- Access4All in Greek Prisons III
20_	- Pilot study to evaluate diagnostic screening using a combined hepatitis c antigen-antibody test in a prison population
22_	- Naloxone Saves Lives
24_	- Mortality among people with psychoactive substance use issues: Epidemiology-Prevention-Response
25_	- Global Fatty Liver Day
26_	- Liver Cancer Awareness Month
27_	- Pilot smoking prevention programme and the value of healthy nutrition at the Special Youth Detention Center of Volos
29_	- Culture and Health Literacy for Equal Access
30_	- Holistic prevention services for people who use psycho-active substances in the field: “Aristotle 2024-2025”
32_	Our Supporters



Promitheas was founded in 2012 as the first Patient Association for liver diseases in Greece. Through its long-standing presence in the field - from prisons and the streets, to the Community Hub and remote border islands - Promitheas has brought to light a deep and multifaceted gap in access to healthcare, particularly for socially and economically vulnerable groups. A gap that goes beyond the boundaries of a single thematic mission and calls for systemic solutions.

In 2025, Promitheas integrates this experience into the core of its identity and evolves into an organisation with an expanded social mission: to defend the universal right of all vulnerable populations to health. Without barriers. Without exclusions.



Promitheas' mission is to ensure that every person has uninterrupted and equal access to quality healthcare services, timely diagnosis, appropriate medical care, and full respect for their fundamental rights.

**Offices:**


213B Alexandras Avenue,
Athens, 11523

Community Hub:


42-44 Favierou Street, Metaxourgeio,
Athens, 10438

Total people reached in 2024:
2.802

People reached from specific
population groups: **2.107***



Specific Population Groups



*The above groups are among hard-to-reach populations with limited access to healthcare services. Our intervention plays a critical role in prevention, access to care, and supporting their social reintegration.

With the support of the TIMA Charitable Foundation, we implemented the “I Deserve to Know Plus” programme during the period **February 2023 - February 2024**.

The aim of the programme was to contribute to improving the health and quality of life of older adults by offering free liver elastography screenings in:




5 remote border islands

(Rhodes, Samos, Astypalaia, Lemnos and Kos)



5 remote areas

(Ioannina, Kavala, Veria, Kozani and Kastoria) within a one-year period.






**Rhodes, Samos, Astypalaia,
Lemnos, Kos, Ioannina,
Kavala, Veroia, Kozani,
Kastoria**



Our medical missions to the five Aegean islands and five remote areas were successfully completed over the course of one year.

In total, we performed **1,017** successful liver elastography examinations.
In detail:



Rhodes 24-28/04/2023 **118**
Samos 22-26/05/2023 **103**
Astypalaia 12-16/06/2023 **80**
Lemnos 10-14/07/2023 **93**
Kos 18-22/09/2023 **95**

Ioannina 23-27/10/2023 **125**
Kavala 20-24/11/2023 **112**
Veroia 11-15/12/2023 **95**
Kozani 22-26/01/2024 **107**
Kastoria 12-16/02/2024 **89**

**A total of 653
medical
examinations
for seniors**

Rhodes: 57
Samos: 53
Astypalaia: 34
Lemnos: 43
Kos: 54


Ioannina: 104
Kavala: 76
Veroia: 72
Kozani: 83
Kastoria: 77

Summary Data on the Elderly:

37,8%
men




62,2%
women




600 people (92%)
underwent a liver
elastography exam
for the first time!

160 people (26,5%)
had liver fibrosis.

- We collaborated with:
- Municipal authorities
 - Medical associations
 - Patient associations
 - Local hepatologists and gastroenterologists for patient referrals
 - Social welfare and solidarity services supporting vulnerable populations
 - Open Care Centres for Older Adults
 - OKANA and KETHEA



[Click on the image to watch the video](#)



[Click on the image to watch the video](#)

The project aims to provide free liver elastography screenings to **600 older adults** over a 12-month period, across **6 remote border areas** of Greece.

From August 2024 to December 2024, we carried out 192 screenings in 2 decentralised areas of the country:

Kos, 14–18 October 2024: 91 screenings, 81 of which were conducted among older adults.

Agrinio, 9–13 December 2024: 101 screenings, 91 of which were conducted among older adults.





Κως, Αγρίνιο,
Βέροια, Καβάλα,
Καλαμάτα, Χανιά



PROJECTS

I Deserve to Know-Plus II



ΜΕ ΤΗΝ ΑΙΓΙΔΑ



ΔΗΜΟΣ ΑΓΡΙΝΙΟΥ



Viral Hepatitis Multi-Country Community Screening, Vaccination and Care (VH-COMSAVAC)



The programme was implemented from November 2022 to April 2025.

VH-COMSAVAC is an innovative programme that aims to reduce the incidence of liver cancer by promoting accurate information on hepatitis B and C, prevention, and harm reduction across Greece, Spain, and Italy. The programme aims to reach at least 600 people in each country.

**Greece:
788 participants in total**

**In 2024, we screened
630 people.**




VIRAL HEPATITIS
COMSAVAC

Multi-Country Community
Screening, Vaccination,
and Care


PROJECTS

Viral Hepatitis Multi-Country Community Screening, Vaccination and Care (VH-COMSAVAC)


Prevalence of HBsAg positivity in Italy, Greece, Spain, and overall.



Prevalence of anti-HCV antibody detection in Italy, Greece, Spain, and in the overall sample.



Overall linkage to specialised medical care among participants with active infection - HBsAg-positive and/or with detectable HCV RNA - was 65.1%:




87.5% (14/16) agreed to receive hepatitis B vaccination.

71.4% (10/14) were screened and vaccinated in correctional facilities.

40% (4/10) of participants were screened through outreach activities and vaccinated at collaborating pharmacies.

100% (16/16) of those who required hepatitis B vaccination were informed of their results.



The Delta Care Project aims to address a dual challenge:

- the increased prevalence of hepatitis D virus and
- the limited awareness surrounding this virus among people in detention at Korydallos Prison I, within the framework of the project “Access4All in Greek Prisons III: Increase Testing Rates for HCV and Linkage to Care.”

Informational and educational materials have been developed in Greek, providing clear information on the transmission, prevention, and treatment of hepatitis D. The materials were scientifically reviewed by the Hellenic Association for the Study of the Liver (HASL) and translated into the following languages in order to reach the corresponding populations within Greek prisons: **Urdu, Georgian, Arabic, Albanian, and English.**

Informational leaflet:

Understanding Hepatitis D: A serious liver infection



What is Hepatitis D?

Hepatitis D, also known as the Hepatitis D Virus (HDV) infection, is a liver disease that is caused by a virus that attacks the liver. It is considered a very serious condition because, if left untreated, it can cause severe liver damage, liver failure, and even death. Hepatitis D is different from other types of Hepatitis because it only affects people who are already infected with Hepatitis B (HBV).

The presence of Hepatitis B is essential for the Hepatitis D virus to replicate, and it can make the symptoms of Hepatitis B much worse. Hepatitis D is considered a "superinfection" that can worsen the existing Hepatitis B infection, making it harder to treat.

Symptoms of Hepatitis D

When someone is infected with Hepatitis D, the symptoms can appear suddenly and can be quite severe. Common symptoms include:

- Fatigue: Feeling very tired or weak, which does not improve with rest.
- Yellowing of the skin and eyes (Jaundice): This occurs when the liver is damaged and cannot process bilirubin properly, leading to a yellow tint in the skin and the whites of the eyes.
- Pain or discomfort in the upper right side of the abdomen: This can be a sign of liver inflammation.
- Nausea and vomiting: The infection can make you feel very sick and cause you to vomit frequently.
- Dark-colored urine: The urine may appear darker than usual.
- Loss of appetite: It may be difficult to eat due to nausea or feeling unwell.

If you notice any of these symptoms, it is very important to seek medical attention immediately.

How is Hepatitis D Transmitted?

Hepatitis D is transmitted through contact with blood that is contaminated with the Hepatitis D virus. This can happen in the following ways:

- Sharing needles or drug-use equipment: This is a very common way to get Hepatitis D. If someone uses a needle that has been used by another person who has Hepatitis B, the virus can be transmitted.
- Unsterile tattoos or piercings: If tattoos or piercings are done with equipment that has been contaminated by another person's blood, you can contract Hepatitis D. It is very important to make sure that the equipment is sterile and that the artist or professional follows proper hygiene practices.
- Unprotected sexual intercourse: Hepatitis D can be spread through sexual contact with someone who is infected with both Hepatitis B and Hepatitis D.
- Sharing personal items like razors or toothbrushes: If an item that comes into contact with blood, such as a razor or toothbrush, is shared, there is a risk of transmission.

It is important to note that Hepatitis D is NOT transmitted through casual contact, such as handshakes, hugging, or kissing.

Who is at Risk for Hepatitis D?

You are at a higher risk of contracting Hepatitis D if you are already infected with Hepatitis B, or if you engage in certain activities that increase the likelihood of being exposed to infected blood. The following groups of people are at greater risk:

- Individuals living with Hepatitis B: Since Hepatitis D can only affect people who have Hepatitis B, those who are infected with Hepatitis B are automatically at risk of getting Hepatitis D if they are exposed to the virus.
- People with a history of substance abuse: Those who use intravenous drugs (e.g., heroin, methamphetamine) and share needles, syringes, or drug paraphernalia are at high risk for contracting Hepatitis D.
- People who get tattoos or piercings without proper precautions: Unregulated tattoo parlors or unlicensed practitioners may not use sterile equipment, which increases the risk of Hepatitis D transmission.
- Individuals who have unprotected sex: Hepatitis D can be transmitted through sexual contact, especially if one person is infected with both Hepatitis B and Hepatitis D.
- People who share personal items: Sharing personal hygiene items, such as razors, toothbrushes, or nail clippers, can lead to blood exposure and the risk of Hepatitis D infection.

How Can You Protect Yourself from Hepatitis D?

Fortunately, there are several ways you can protect yourself from contracting Hepatitis D. These precautions are vital to your health, particularly in environments where the risk of blood exposure is higher. Here are some steps to follow:

1. Get Vaccinated Against Hepatitis B: Since Hepatitis D can only affect people who are already infected with Hepatitis B, getting the Hepatitis B vaccine is the first and most important step to protect yourself. The vaccine is highly effective at preventing Hepatitis B infection, and by doing so, you also prevent Hepatitis D.
2. Avoid Sharing Needles and Drug Equipment: Never share needles, syringes, or any other equipment used for drug use. Even a small amount of blood left on equipment can transmit

Informational leaflet:

the virus.

3. Use Safe and Sterile Methods for Tattoos and Piercings: Make sure to get tattoos or piercings only at licensed and regulated establishments that use sterile needles and equipment. Do not get tattoos or piercings in unsafe or unregulated conditions.
4. Practice Safe Sex: Always use a condom during sexual activity, particularly if you or your partner have Hepatitis B. This will reduce the risk of transmitting or contracting Hepatitis D (and other sexually transmitted infections).
5. Avoid Sharing Personal Items: Do not share razors, toothbrushes, or any other personal hygiene items that might come into contact with blood. Blood from a person infected with Hepatitis B and D can contaminate these items, putting you at risk.
6. Follow Proper Hygiene and Cleanliness: Make sure that any objects or tools that come into contact with your body (such as razors, clippers, etc.) are clean and properly sterilized to prevent the spread of the virus.

Get Tested – It Could Save Your Life!



Early diagnosis and treatment are key to preventing serious liver damage and complications. If you think you may be at risk for Hepatitis D, it is essential to get tested. Testing is quick, easy, and confidential, and it can help you get the care and treatment you need early.

- Consult the prison doctor today for testing.
- Results are always confidential – your health is important, and your privacy is protected.
- Early treatment can save lives.

Your Health Matters – Stay Safe and Protect Yourself!

About Prometheus

Prometheus was founded and has been active since 2012, with the mission to ensure that health service recipients have universal access to health care, timely diagnosis, appropriate health care, and respect for their inalienable rights. The Association aims to reduce social inequalities by ensuring equal access to health services for all, regardless of socio-economic level.

helpa-prometheus.gr

Comprehensive Awareness and Information Campaign on Liver Cancer. Implemented since October 2020 in remote border areas.



The “It Works for You!” programme in **Agrinio:**

- 9-20 December 2024 - under the auspices of the Municipality of Agrinio and the Medical Association of Agrinio.
- Implemented in collaboration with the Association of People with Diabetes of Aetolia-Acarnania “Glykia Oikogeneia”, the Agrinio Volunteer Blood Donors Association, the Volunteer Network of the Municipality of Agrinio, and the Agrinio Thalassemia Association.

A total of **130 free liver elastography screenings** were conducted. In collaboration with the General University Hospital of Patras for patient referrals.



Agrinio Stands with Vulnerable Groups

The programme targeted the general population aged 45-70, with a focus on groups at higher risk of chronic liver disease, including people living with obesity, diabetes mellitus, a history of alcohol misuse, or exposure to hepatitis viruses. Particular emphasis was placed on mountainous and island areas, as well as on economically vulnerable community members.



Kastoria, 12-16 February 2024

Under the auspices of the Deputy Mayoral Office for Social Policy, Help at Home and Preschool Education of the Municipality of Kastoria, and the Medical Association of Kastoria, in collaboration with:

- Department for the Protection and Promotion of Public Health - Social Clinic of the Municipality of Kastoria
- Association of People with Diabetes of Kastoria
- Association of Parents of Children and Adults with Neoplastic Disease and their Friends “MAZI SOU”
- Open Care Centre for Older Adults of Kastoria

A total of **89 free liver elastography screenings** were conducted at the Social Clinic of Kastoria.





Kos, 14–18 October 2024

Under the auspices of the Municipality of Kos, the Deputy Mayoral Office for Social Policy and Welfare, and the Medical Association of Kos “Hippocrates”, in collaboration with:

- the Community Centre
- the Community Centre with Roma Branch
- the 1st Municipal Friendship Club of the Municipality of Kos

In total, **91 free liver elastography screenings** were carried out at the General Hospital - Health Centre of Kos “Hippocrateion”.

**TARGET**

To screen 1,200 people in detention for hepatitis C.

From September to December 2024, 358 people in detention were screened at Thessaloniki Correctional Facility.

Average age: 39.1 years
Nationality: 52.8% Greek

Next intervention → Korydallos Prison I

HCV

Previously tested:	67,0% (240/358)
Anti-HCV positive:	17,0% (61/358)
Received treatment among those who tested positive:	36,1% (22/61)
Had AMKA/PAYPEK:	98,4% (60/61)
Chronic HCV infection:	62,5% (30/48)
Registered in the national registry:	100% (30/30)
DAAs prescribed:	93,3% (28/30)
Initiated treatment:	71,4% (20/28)
Released before treatment initiation:	2

HBV

Previously tested:	65,9% (236/358)
HBsAg-positive:	1,7% (6/358)

HIV

Previously tested:	66,2% (237/358)
HIV-positive:	2,2% (8/358)
Unaware of their infection:	62,5% (5/8)
Receiving treatment within the correctional facility:	3/8

Pilot Study to Evaluate Diagnostic Screening Using a Combined Hepatitis C Antigen-Antibody Test among People in Detention



Evaluation of the HCVAg component of the Elecsys® HCV Duo test for HCV infection screening among people in detention, compared with standard screening practice.

Study site: Korydallos Prison I

**Sample collection period:
March – June 2024**

**Participants: 780 people in
detention**

Randomised into two groups

- In Group 1 (standard practice), participants were screened for anti-HCV using a rapid test. In the case of a positive result, blood sampling followed, along with HCV RNA testing and supplementary testing with Elecsys® HCV Duo (anti-HCV and HCVAg).
- In Group 2, blood sampling was performed and participants were tested with Elecsys® HCV Duo. If the result was positive, participants were invited for a second blood sample for HCV RNA testing. The sensitivity and specificity of HCVAg were evaluated using HCV RNA as the reference method.

Φορέας Υλοποίησης:



Σε συνεργασία με:



Pilot Study to Evaluate Diagnostic Screening Using a Combined Hepatitis C Antigen-Antibody Test among People in Detention

Results

HCV prevalence:

- 19.8% tested positive for HCV antibodies.
- Among them, 60.9% were HCV RNA-positive.

HCV RNA testing:

- HCV RNA testing was performed in 128 people in detention.
- Detectable HCV RNA: 78 people in detention (60.9%).

Linkage to healthcare services:

60 people received treatment and were registered in the hepatitis C treatment registry.

Conclusion



The use of Elecsys® HCV Duo could facilitate one-step diagnosis of hepatitis C, particularly among populations such as people in detention. Although it showed lower sensitivity compared with HCV RNA, it demonstrated a high positive predictive value.

Naloxone Saves Lives – Awareness Campaign on Opioid Overdose Response



The City of Athens was awarded within the framework of the Partnership for Healthy Cities (PHC) for its opioid overdose response programme for people who use opioids. The award was presented by Michael Bloomberg at the 1st PHC Summit in London.

Planning and implementation bodies:

Promitheas, in collaboration with the Hellenic Scientific Society for the Study of AIDS, Sexually Transmitted and Emerging Diseases.

The Hellenic Parliament adopted a new amendment enabling people directly affected, their peers, and those close to them to possess and administer naloxone in cases of immediate need.

Promitheas implemented the “**Naloxone Saves Lives**” campaign, which was launched on Valentine’s Day, 14 February 2024, and concluded on the International Day Against Drug Abuse and Illicit Trafficking, 26 June.

PROJECTS

Naloxone Saves Lives – Awareness Campaign on Opioid Overdose Response



Article published on 14 February 2024:
“Valentine’s Day: A Heart Beats for People Who Use Substances” by our Media Sponsor, HuffPost, along with promotion of the campaign on the website:



Our webpages received more than 25,000 clicks.

[CLICK ON THE IMAGE TO VISIT OUR WEBSITE](http://www.naloxonesaveslives.gr)

Mortality Among People with Psychoactive Substance Use Issues: Epidemiology – Prevention – Response I Scientific Meeting

Ημερίδα

Θνησιμότητα σε άτομα με προβλήματα χρήσης ψυχοδραστικών ουσιών: Επιδημιολογία – Πρόληψη – Αντιμετώπιση

12 Μαρτίου 2024
9.00-17.00
Αμφιθέατρο ΕΠΙΨΥ
 Σωρανού του Εφεσίου 2
 11527 Αθήνα

Conference

Drug-related deaths and mortality in people who use drugs: Epidemiology and Responses

March 12, 2024
9.00-17.00
UMHRI Lecture Hall
 2 Soranou tou Efesiou
 11527 Athens

Ζωντανή αναμετάδοση / Live streaming:
[youtube.com/@umhriepipsi](https://www.youtube.com/@umhriepipsi)
 Πληροφορίες, πρόγραμμα, εγγραφή / Details, Agenda, Registration:
<https://www.ektepn.gr/news/mortality-conference-march2024>

Διοργάνωση / Organised by


Υπό την αιγίδα



The aim was to highlight the need for surveillance and prevention of deaths related to psychoactive substance use, with the contribution of leading experts from Greece and abroad.

Global Fatty Liver Day

Informing and raising public awareness about fatty liver disease through publications across Promitheas' communication channels.



Liver Cancer Awareness Month Information and Awareness Campaign




[CLICK ON THE IMAGE TO WATCH THE INFORMATIVE VIDEO](#)

OBJECTIVES:

- To inform and raise public awareness about the importance of early diagnosis of liver cancer;
- to promote prevention, strengthen access to free liver elastography, and reduce mortality from diseases that are treatable when detected early.

Pilot Smoking Prevention Programme and the Value of Healthy Nutrition and Exercise at the Special Youth Detention Centre of Volos



Adoption of positive habits to prevent disease and improve the quality of life of people in detention.

- Informing and educating young adults in detention about the negative long-term effects of smoking on their health.
- Promoting healthy nutrition and regular physical activity among people in detention.
- Adapting and integrating changes within the correctional facility.

PROJECT IMPACT:

Empowerment of participants, strengthening of their self-esteem, and increased prospects for successful reintegration into society; improvement of health literacy among people in detention; development of proposals for systemic interventions to be adopted by the correctional system and serve as good practice; promotion of primary prevention; and adoption of a healthy lifestyle both during young people's stay in the cor-

Health
is not
a privilege
but a
human
right.

OBJECTIVE:

rectional facility and upon their return to the community.

To facilitate citizens' understanding of and active participation in their own healthcare, by strengthening health literacy and equal access to health services.

PART 1:

Short reel-format videos, to be promoted mainly on TikTok, covering the following topics:

- Viral hepatitis
- Hepatocellular carcinoma
- Alcoholic hepatitis
- Non-alcoholic hepatitis
- Fatty liver disease
- Early diagnosis
- Vaccination

PART 2:

A video featuring the key people involved in the study evaluating diagnostic screening using a combined hepatitis C antigen-antibody test among people in detention at Korydallos Prison. The study was implemented in 2024 with the support of Roche. Filming is currently in the final stages of completion.

Its' purpose is to highlight the importance of equal access to healthcare for people in detention and to raise public awareness of the barriers and stigma they face.



Promitheas is a partner of the organisation THERENA, with which it jointly implements the programme:

«Holistic Access Services for People Who Use Psychoactive Substances»

This programme is addressed to vulnerable populations, such as people who use psychoactive substances, and is implemented in the field and at the Community Hub, located at 42-44 Favierou Street, Metaxourgeio.

Holistic Prevention Services for People Who Use Psychoactive Substances in the Field: “ARISTOTLE 2024-2025”



October 2024 - April 2025.

Methodology:

Respondent-driven sampling (RDS) using coupons

OBJECTIVE


To contribute to reducing hepatitis C and HIV transmission, while increasing diagnosis and linkage to care and treatment among people who inject drugs (PWID) in the Municipality of Athens.

Holistic Prevention Services for People Who Use Psychoactive Substances in the Field: “ARISTOTLE 2024–2025”

Specific objectives of the programme:


- Increase diagnosis through HCV and HIV screening among people who use psychoactive substances in the intervention area, with peer-led outreach and engagement.
- Increase linkage to appropriate treatment and care through National Health System services.
- Evaluate the effectiveness of a community-based holistic programme for screening, linkage to care, and treatment initiation for hepatitis C and HIV among people who use psychoactive substances.
- Map the cascade of care for HCV and HIV among people who use psychoactive substances.

PROJECT STAGES:



October - December 2024:
336 participants

The programme is expected to reach
600 unique people who use
psychoactive substances by April 2025.

A close-up photograph showing a person's finger being held by a hand wearing a blue nitrile glove. A small drop of blood is visible on the fingertip, and a clear microcentrifuge tube is positioned to collect it. The background is blurred, showing more of the gloved hand and the person's skin.

The Promitheas team has
succeeded in reaching a large
number of people from
vulnerable social groups, often
under extremely challenging
conditions.

For us, health is an inalienable
right - regardless of what
someone has done or where
they are.



Bayer

ΘΕΤΙΚΗ ΦΩΝΗ
άνδρωναί+HIV



John S. Latsis
Public Benefit Foundation



abbvie



GILEAD
Creating Possible



GLOBAL
LIVER
INSTITUTE



Hospital
line



Evidera

PPD



Vital
Strategies



BIANEX A.E.
ΒΙΟΜΗΧΑΝΙΑ ΦΑΡΜΑΚΩΝ
ΕΤΑΙΡΕΙΑ ΤΟΥ ΟΜΙΛΟΥ ΓΙΑΝΝΑΚΟΠΟΥΔΟΥ

TIMA

CHARITABLE FOUNDATION ΚΟΙΝΩΦΕΛΕΣ ΙΔΡΥΜΑ

Roche Diagnostics International Ltd.



ΕΛΛΗΝΙΚΗ ΕΠΙΣΤΗΜΟΝΙΚΗ ΕΤΑΙΡΕΙΑ ΕΡΕΥΝΑΣ AIDS
ΚΑΙ ΣΕΞΟΥΑΛΙΚΩΣ ΜΕΤΑΔΙΔΟΜΕΝΩΝ ΝΟΣΗΜΑΤΩΝ



ΙΔΡΥΜΑ
ΜΠΟΔΟΣΑΚΗ

Memberships



ΕΛΛΗΝΙΚΗ ΔΗΜΟΚΡΑΤΙΑ
Υπουργείο Κοινωνικής Συνοχής
και Οικογένειας



ΕΛΛΗΝΙΚΗ ΔΗΜΟΚΡΑΤΙΑ
ΠΕΡΙΦΕΡΕΙΑ ΑΤΤΙΚΗΣ



Promitheas

 (+30) 211 012 2102

 info@promitheasngo.com

 213B Alexandras Avenue, Ampelokipoi, Athens

Facebook facebook.com/promitheasngo

Instagram instagram.com/promitheas_ngo

TikTok www.tiktok.com/@promitheas_ngo

LinkedIn linkedin.com/company/promitheasngo

Youtube youtube.com/user/HLPAPrometheus

Website www.promitheasngo.com